接受免疫检查点抑制剂治疗的非小细胞肺癌患者治疗前干扰素-γ释放的意义。
Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
机构信息
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
出版信息
Anticancer Res. 2020 Dec;40(12):6971-6978. doi: 10.21873/anticanres.14721. Epub 2020 Dec 7.
BACKGROUND/AIM: We retrospectively investigated the significance of pre-treatment interferon-gamma release (IGR) as a biomarker for predicting the efficacy of immune checkpoint inhibitor treatment (ICI-tx).
PATIENTS AND METHODS
This study included non-small-cell lung cancer patients who received ICI-tx between January 1, 2016 and April 30, 2019. IGR was measured using the positive control of an enzyme-linked immunosorbent assay. We defined the pre-treatment cut-off level of IGR as 10 IU/ml.
RESULTS
Fifty-four patients were divided into two groups; those with an IGR ≤10 IU/ml (lower group: LG) (n=15) and those with >10 IU/ml (higher group: HG) (n=39). The time to treatment failure (TTF) in the HG was significantly longer than that in the LG. In multivariate analyses, C-reactive protein and IGR levels were significant risk factors for TTF.
CONCLUSION
Pre-treatment IGR level of >10 IU/ml is recommended to identify those patients who will respond favourably to ICI-tx.
背景/目的：我们回顾性研究了治疗前干扰素-γ释放（IGR）作为预测免疫检查点抑制剂治疗（ICI-tx）疗效的生物标志物的意义。
患者和方法
本研究纳入了 2016 年 1 月 1 日至 2019 年 4 月 30 日期间接受 ICI-tx 的非小细胞肺癌患者。IGR 采用酶联免疫吸附测定的阳性对照进行测量。我们将 IGR 的治疗前截断值定义为 10IU/ml。
结果
54 例患者分为两组；IGR≤10IU/ml（低组：LG）（n=15）和>10IU/ml（高组：HG）（n=39）。HG 的治疗失败时间（TTF）明显长于 LG。多变量分析显示，C 反应蛋白和 IGR 水平是 TTF 的显著危险因素。
结论
建议治疗前 IGR 水平>10IU/ml 以识别对 ICI-tx 反应良好的患者。
Zotero 插件